A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer
Authors
Keywords
-
Journal
Cancer Medicine
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-07-26
DOI
10.1002/cam4.2425
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Notch Suppresses Angiogenesis and Progression of Hepatic Metastases
- (2015) D. Banerjee et al. CANCER RESEARCH
- Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency
- (2015) W.-C. Yen et al. CLINICAL CANCER RESEARCH
- Final results of phase Ib of anticancer stem cell antibody tarextumab (OMP-59R5, TRXT, anti-Notch 2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).
- (2015) Eileen Mary O'Reilly et al. JOURNAL OF CLINICAL ONCOLOGY
- Stem cells living with a Notch
- (2013) U. Koch et al. DEVELOPMENT
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patient-derived tumour xenografts as models for oncology drug development
- (2012) John J. Tentler et al. Nature Reviews Clinical Oncology
- Notch3 and Hey-1 as Prognostic Biomarkers in Pancreatic Adenocarcinoma
- (2012) Christopher D. Mann et al. PLoS One
- Notch and Kras in pancreatic cancer: At the crossroads of mutation, differentiation and signaling
- (2011) Jean-Paul De La O et al. CELL CYCLE
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Notch1 Functions as a Tumor Suppressor in a Model of K-ras–Induced Pancreatic Ductal Adenocarcinoma
- (2010) Linda Hanlon et al. CANCER RESEARCH
- Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma
- (2010) P. K. Mazur et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibition of γ-Secretase Activity Inhibits Tumor Progression in a Mouse Model of Pancreatic Ductal Adenocarcinoma
- (2009) Ruben Plentz et al. GASTROENTEROLOGY
- CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells
- (2009) Sung Pil Hong et al. INTERNATIONAL JOURNAL OF CANCER
- Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway
- (2009) Jun Yao et al. MEDICAL ONCOLOGY
- Vascular normalization in Rgs5-deficient tumours promotes immune destruction
- (2008) Juliana Hamzah et al. NATURE
- Colorectal Cancer Stem Cells Are Enriched in Xenogeneic Tumors Following Chemotherapy
- (2008) Scott J. Dylla et al. PLoS One
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search